Experts:
Professor Andreas Hochhaus
Director of the Department of Hematology and Medical Oncology
Jena University Hospital (Germany)

Professor Tiong S Ong
Duke-NUS Medical School (Singapore) &
Duke University Medical Center, NC (USA)

00:00 Welcome & Introduction
00:53 Clinical highlights:
03:04 Balancing tolerability and efficacy goals of patients and physicians through shared treatment decision-making
06:22 Selectivity of kinase inhibitors
06:57 ASCEMBL study results
09:11 Asciminib resistance mutations (from published studies)
10:26 Combination therapy of asciminib and ponatinib was effective in the treatment of blast phase CML CDX model
11:35 Rough guide to 3L+ therapies
13:23 TIGER study results
16:22 FASCINATION German CML XI study results
17:57 Prognostic factors for 3-year MMR maintenance in CML patients in the EURO-SKI trial
21:02 Biological highlights:
22:59 Current areas of translational research interest in chronic myeloid leukemia
26:54 Combination of large spleen size and low in vivo kinase inhibition in an early predictor of inferior molecular response for patients with CML
32:38 What can we learn from single cell studies in chronic myeloid leukemia?
37:48 Drug profiling for CML blast crisis
40:41 Identification of novel factors controlling non genetic cell plasticity in chronic myeloid leukemia
43:05 Mechanisms of trombogenesis in patients with chronic myeloid leukemia under treatment with ponatinib and other TKIs
45:01 Timing and clonal trajectory to chronic myeloid leukemia driven by the Philadelphia chromosome
48:20 Q&A Session

свернуть